"""
Question: 1101 

Evidence: This is a retrospective analysis of adult (≥18 years) people living with HIV attending public healthcare facilities. Samples from 544 patients (494 plasma samples and 50 DBS) were included.

Rationale: The study describes original data collected from 544 patients with specific laboratory analyses (drug resistance and drug exposure testing) that were conducted and reported by the authors, indicating previously unpublished data.

Answer: Yes
"""

"""
Question: 1102 

Evidence: Population genotypic drug resistance testing of the pol region was performed on plasma and DBS using standard clinical protocols. Sequences were submitted to Genbank (accession number # 2343427).

Rationale: The paper explicitly states that pol region genotypic sequencing was performed and that sequences were submitted to GenBank, confirming that HIV sequences are reported.

Answer: Yes
"""

"""
Question: 1103 

Evidence: This is a retrospective analysis of adult (≥18 years) people living with HIV attending public healthcare facilities. Population genotypic drug resistance testing of the pol region was performed on plasma and DBS using standard clinical protocols.

Rationale: The study involves clinical samples with genotypic testing; there is no mention of laboratory in vitro passage experiments, indicating such experiments were not performed.

Answer: No
"""

"""
Question: 1104 

Evidence: Population genotypic drug resistance testing of the pol region was performed on plasma and DBS using standard clinical protocols. Diagnostic accuracy of LPV exposure testing as a marker for LPV/r resistance was reported as sensitivity, specificity, and positive/negative predictive value.

Rationale: The paper reports genotypic analyses and drug exposure testing, not phenotypic susceptibility assays or IC values, indicating no in vitro antiretroviral susceptibility data.

Answer: No
"""

"""
Question: 2101 

Evidence: Sequences were submitted to Genbank (accession number # 2343427). Population genotypic drug resistance testing of the pol region was performed on plasma and DBS using standard clinical protocols.

Rationale: The authors state that sequences were submitted to GenBank and provide an accession number, confirming GenBank accession reporting.

Answer: Yes
"""

"""
Question: 2102 

Evidence: This is a retrospective analysis of adult (≥18 years) people living with HIV attending public healthcare facilities. Sequences were submitted to Genbank (accession number # 2343427).

Rationale: The sequences derive from clinical patient samples rather than laboratory strains, so the reported accession numbers correspond to clinical (non-lab) HIV isolates.

Answer: Yes
"""

"""
Question: 2103 

Evidence: Sequences were submitted to Genbank (accession number # 2343427). Population genotypic drug resistance testing of the pol region was performed on plasma and DBS using standard clinical protocols.

Rationale: The only accession identifier provided is “# 2343427,” which the paper explicitly cites for the submitted sequences.

Answer: 2343427
"""

"""
Question: 2202 

Evidence: Population genotypic drug resistance testing of the pol region was performed on plasma and DBS using standard clinical protocols. Frequency of mutational patterns in protease detected by Sanger sequencing conferring ritonavir-boosted lopinavir (LPV/r) drug resistance in 138 patients.

Rationale: The paper summarizes resistance mutation frequencies and patterns but does not present per-sample mutation lists for individual isolates.

Answer: No
"""

"""
Question: 2301 

Evidence: Patients were infected with HIV-1 subtype C in 98.9% (538/544) of cases. All 544 included patients had documented virological failure of LPV/r-based second-line ART.

Rationale: The explicit mention of HIV-1 subtype C indicates the species was HIV-1.

Answer: HIV-1
"""

"""
Question: 2302 

Evidence: Patients were infected with HIV-1 subtype C in 98.9% (538/544) of cases. 

Rationale: The paper reports that nearly all sequenced viruses were subtype C.

Answer: Predominantly subtype C (98.9%)
"""

"""
Question: 2303 

Evidence: Population genotypic drug resistance testing of the pol region was performed on plasma and DBS using standard clinical protocols. The majority of patients harboured either I54V + V82A or I54V + L76V + V82A.

Rationale: The mention of pol region sequencing with detailed protease mutations and RT mutation M184V indicates sequencing of pol, specifically protease and reverse transcriptase.

Answer: pol (protease and reverse transcriptase)
"""

"""
Question: 2304 

Evidence: Population genotypic drug resistance testing of the pol region was performed on plasma and DBS using standard clinical protocols. 

Rationale: Since pol region sequences were generated and analyzed, the paper reports results of HIV pol sequences.

Answer: Yes
"""

"""
Question: 2401 

Evidence: Plasma samples were analysed at the National Health Laboratory Services laboratory at Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa. The study was also implemented at a large rural primary healthcare facility based in Limpopo, South Africa.

Rationale: Both sites are in South Africa, specifying the geographic origins of the sequences.

Answer: South Africa (Johannesburg and Limpopo; multiple provinces)
"""

"""
Question: 2402 

Evidence: We included patients who received plasma-based drug resistance testing at a central South African reference laboratory in 2017 and patients who received dried blood spots (DBS)-based drug resistance testing at a rural South African clinic between 2009 and 2017. 

Rationale: The paper clearly states the collection years for plasma and DBS groups.

Answer: 2009–2017 (plasma in 2017; DBS between 2009 and 2017)
"""

"""
Question: 2502 

Evidence: Frequency of mutational patterns in protease detected by Sanger sequencing conferring ritonavir-boosted lopinavir (LPV/r) drug resistance in 138 patients. Population genotypic drug resistance testing of the pol region was performed on plasma and DBS using standard clinical protocols.

Rationale: The table explicitly states Sanger sequencing was used.

Answer: Yes
"""

"""
Question: 2503 

Evidence: Frequency of mutational patterns in protease detected by Sanger sequencing conferring ritonavir-boosted lopinavir (LPV/r) drug resistance in 138 patients. 

Rationale: The methods and table indicate Sanger sequencing; there is no mention of next-generation sequencing.

Answer: No
"""

"""
Question: 2504 

Evidence: Population-based genotypic drug resistance testing was performed using previously described methods for plasma and for DBS. Frequency of mutational patterns in protease detected by Sanger sequencing conferring ritonavir-boosted lopinavir (LPV/r) drug resistance in 138 patients.

Rationale: The paper does not state that molecular cloning or sample cloning was performed prior to sequencing; no cloning details are provided.

Answer: NA
"""

"""
Question: 2505 

Evidence: Population-based genotypic drug resistance testing was performed using previously described methods for plasma and for DBS. Frequency of mutational patterns in protease detected by Sanger sequencing conferring ritonavir-boosted lopinavir (LPV/r) drug resistance in 138 patients.

Rationale: There is no mention of single-genome sequencing; only population (bulk) sequencing is described.

Answer: NA
"""

"""
Question: 2506 

Evidence: Population-based genotypic drug resistance testing was performed using previously described methods for plasma and for DBS. 

Rationale: The paper does not describe molecular cloning; therefore, whether samples underwent molecular cloning cannot be determined.

Answer: NA
"""

"""
Question: 2601 

Evidence: Population genotypic drug resistance testing of the pol region was performed on plasma and DBS using standard clinical protocols. Patients received drug resistance testing on EDTA-derived plasma as part of clinical care.

Rationale: The study performed and reported plasma-based HIV genotypic sequencing.

Answer: Yes
"""

"""
Question: 2602 

Evidence: Population genotypic drug resistance testing of the pol region was performed on plasma and DBS using standard clinical protocols. 

Rationale: PBMC-based sequencing is not mentioned; sample types were plasma and DBS.

Answer: No
"""

"""
Question: 2603 

Evidence: From 500 patients selected for plasma-based testing, 494 patients were included. Patients received drug resistance testing on EDTA-derived plasma as part of clinical care.

Rationale: The number of plasma samples included for drug resistance testing (i.e., sequencing) was 494.

Answer: 494
"""

"""
Question: 2604 

Evidence: Population genotypic drug resistance testing of the pol region was performed on plasma and DBS using standard clinical protocols. 

Rationale: PBMC sequencing was not performed or reported; thus, the number is zero.

Answer: 0
"""

"""
Question: 2605 

Evidence: Patients were included if they experienced confirmed virological failure according to South African guidelines, defined as viraemia ≥1000 copies/mL for at least six months, after at least one year of PI-based second-line ART. 

Rationale: Inclusion required active viremia, indicating ongoing HIV replication at sampling.

Answer: Yes
"""

"""
Question: 2606 

Evidence: Population genotypic drug resistance testing of the pol region was performed on plasma and DBS using standard clinical protocols. Per patient, five drops of 50 µL of EDTA-derived whole blood were spotted on a Protein Saver 903 card … samples were shipped … drug resistance testing was performed.

Rationale: Sequencing was from plasma and DBS (RNA-based); there is no indication of sequencing from proviral DNA reservoirs.

Answer: No
"""

"""
Question: 2701 

Evidence: This is a retrospective analysis of adult (≥18 years) people living with HIV attending public healthcare facilities. 

Rationale: The cohort consisted of adults; no infants or children were included.

Answer: No
"""

"""
Question: 2702 

Evidence: Patients received drug resistance testing on EDTA-derived plasma as part of clinical care. Drug resistance testing was requested and successfully performed in clinical practice.

Rationale: The study used routine clinical care samples, not clinical trial participants.

Answer: No
"""

"""
Question: 2703 

Evidence: Patients received drug resistance testing … as part of clinical care. Drug resistance testing was requested and successfully performed in clinical practice.

Rationale: Since the study was based on routine clinical practice, not all participants were in a clinical trial.

Answer: No
"""

"""
Question: 3101 

Evidence: From 500 patients selected for plasma-based testing, 494 patients were included. Fifty patients were selected for DBS-based testing and all were included.

Rationale: Total individuals with samples for sequencing equals 494 (plasma) + 50 (DBS) = 544.

Answer: 544
"""

"""
Question: 3102 

Evidence: Patients were included if … drug resistance was requested and successfully performed in clinical practice. Population genotypic drug resistance testing of the pol region was performed on plasma and DBS using standard clinical protocols.

Rationale: Inclusion required successful drug resistance testing; therefore, all included individuals underwent HIV sequencing.

Answer: Yes
"""

"""
Question: 4101 

Evidence: Patients were included if they were receiving treatment with LPV/r-based second-line ART. All patients received LPV/r with a dual NRTI backbone.

Rationale: All participants were ART-experienced and on second-line therapy; none were ART-naive.

Answer: No
"""

"""
Question: 4102 

Evidence: Patients were included if they were receiving treatment with LPV/r-based second-line ART. All patients received LPV/r with a dual NRTI backbone.

Rationale: This indicates prior ARV exposure (first-line) and current second-line therapy, i.e., ART-experienced.

Answer: Yes
"""

"""
Question: 4103 

Evidence: Patients were included if they were receiving treatment with LPV/r-based second-line ART. All patients received LPV/r with a dual NRTI backbone.

Rationale: The study only includes ART-experienced individuals; no ART-naive subjects are included.

Answer: No
"""

"""
Question: 4104 

Evidence: Patients were included if they were receiving treatment with LPV/r-based second-line ART. 

Rationale: Being on second-line implies prior ART; thus, there were no ART-naive samples.

Answer: 0
"""

"""
Question: 4105 

Evidence: Data on treatment history and duration were not available for patients in the plasma sample group. 

Rationale: Because treatment history was missing for the plasma group, complete ART history for all individuals is not provided.

Answer: No
"""

"""
Question: 4201 

Evidence: We studied the value of recent PI-exposure … in patients with virological failure on second-line ART. In this analysis, only a minority of patients with virological failure harboured PI-resistant virus.

Rationale: The focus is on acquired resistance during second-line failure; there is no assessment of transmitted resistance prevalence.

Answer: No
"""

"""
Question: 4202 

Evidence: We studied … patients with virological failure on second-line ART. Population-based drug resistance testing can be unreliable in case of non-adherence … 

Rationale: The paper does not analyze pretreatment (baseline, pre-ART) resistance; it assesses resistance at second-line failure.

Answer: No
"""

"""
Question: 4301 

Evidence: All patients received LPV/r with a dual NRTI backbone. World Health Organization guidelines recommend … a ritonavir-boosted protease inhibitor (PI) … combined with a dual NRTI backbone.

Rationale: The regimens given to study participants were protease inhibitors (LPV/r) plus NRTIs.

Answer: Protease inhibitors and nucleos(t)ide reverse transcriptase inhibitors
"""

"""
Question: 4302 

Evidence: All patients received LPV/r with a dual NRTI backbone. Screening for detectable levels of other antiretroviral anchor drugs (… raltegravir) was also performed to exclude any unreported use.

Rationale: The described regimens do not include integrase inhibitors; raltegravir was only screened to exclude unreported use.

Answer: No
"""

"""
Question: 4303 

Evidence: All patients received LPV/r with a dual NRTI backbone. Second-line regimen … consisting of a ritonavir-boosted protease inhibitor (PI), either lopinavir (LPV/r) or atazanavir (ATV/r).

Rationale: The cohort was on PI-based second-line ART.

Answer: Yes
"""

"""
Question: 4304 

Evidence: All patients received LPV/r with a dual NRTI backbone. Second-line NRTI backbone: AZT/3TC 62.1%, TDF/3TC 18.9%, ABC/3TC 13.8%, Other 5.1%.

Rationale: Although all received LPV/r, the NRTI backbones varied across individuals; hence, not all received the exact same ART regimen.

Answer: No
"""

"""
Question: 4305 

Evidence: Screening for detectable levels of other antiretroviral anchor drugs (… raltegravir) was also performed to exclude any unreported use. All patients received LPV/r with a dual NRTI backbone.

Rationale: No integrase inhibitors were part of the reported regimens, and screening aimed to rule out any unreported use, indicating INSTI-naive status.

Answer: Yes
"""

"""
Question: 4403 

Evidence: Patients were included if they were receiving treatment with LPV/r-based second-line ART. All 544 included patients had documented virological failure of LPV/r-based second-line ART.

Rationale: Being on second-line implies at least two ART regimens; therefore, all 544 individuals received more than one regimen.

Answer: 544
"""

"""
Question: 4404 

Evidence: Patients were included if they were receiving treatment with LPV/r-based second-line ART. 

Rationale: The paper does not report how many, if any, received third or additional regimens beyond second-line.

Answer: NA
"""

"""
Question: 4405 

Evidence: Second-line NRTI backbone varied (AZT/3TC, TDF/3TC, ABC/3TC, Other). Data on treatment history and duration were not available for patients in the plasma sample group.

Rationale: The number of regimens per individual is not comprehensively reported, so it cannot be determined whether all received the same number of regimens.

Answer: NA
"""

"""
Question: 4406 

Evidence: Patients were included if they were receiving treatment with LPV/r-based second-line ART. 

Rationale: Being on second-line therapy means they did not receive only one regimen.

Answer: No
"""

"""
Question: 4501 

Evidence: All patients received LPV/r with a dual NRTI backbone. The recent development of POC tests … may pave the way for future implementation … DTG has a high barrier to resistance …

Rationale: Regimens did not include dolutegravir; DTG is mentioned only in discussion as context, not as received therapy.

Answer: 0
"""

"""
Question: 4502 

Evidence: All patients received LPV/r with a dual NRTI backbone. Cross-resistance to darunavir/ritonavir … was present in 55.1% of cases.

Rationale: The study assessed genotypic cross-resistance to darunavir but did not treat patients with darunavir.

Answer: 0
"""

"""
Question: 5101 

Evidence: Mutations conferring resistance to NRTIs were detected in 70.6% (349/494) of plasma samples and 56.0% (28/50) of DBS. Mutations conferring resistance to NNRTIs were detected in 64.2% (317/494) of plasma samples and in 54.0% (27/50) of DBS.

Rationale: Although per-class resistance prevalences are given, the paper does not provide an overall count of individuals with one or more mutations across any class, and overlaps are unknown.

Answer: NA
"""

"""
Question: 5102 

Evidence: Population genotypic drug resistance testing of the pol region was performed on plasma and DBS using standard clinical protocols. Screening for detectable levels of other antiretroviral anchor drugs … raltegravir … was also performed to exclude any unreported use.

Rationale: Integrase (IN) sequencing or INSTI resistance testing was not performed; therefore, the number with INSTI-resistance mutations cannot be determined.

Answer: NA
"""

"""
Question: 5103 

Evidence: Mutations conferring resistance to NRTIs were detected in 70.6% (349/494) of plasma samples and 56.0% (28/50) of DBS. 

Rationale: The paper does not disaggregate NRTI resistance by specific drugs such as TDF; counts for TDF-resistance mutations are not reported.

Answer: NA
"""

"""
Question: 5104 

Evidence: Population genotypic drug resistance testing of the pol region was performed on plasma and DBS using standard clinical protocols. 

Rationale: No integrase sequencing was performed; thus, no INSTI-resistance mutations were reported.

Answer: NA
"""

"""
Question: 6101 

Evidence: Population genotypic drug resistance testing of the pol region was performed on plasma and DBS using standard clinical protocols. Diagnostic accuracy of LPV exposure testing … was reported as sensitivity, specificity, and positive/negative predictive value.

Rationale: The study did not perform phenotypic susceptibility testing; it focused on genotypic testing and drug level (exposure) testing.

Answer: NA
"""

"""
Question: 6102 

Evidence: Diagnostic accuracy of LPV exposure testing … was reported as sensitivity, specificity, and positive/negative predictive value. 

Rationale: IC values (e.g., IC50, IC90) are not reported, as no phenotypic assays were conducted.

Answer: No
"""

"""
Question: 6103 

Evidence: Population genotypic drug resistance testing … was performed … Diagnostic accuracy of LPV exposure testing … was reported as sensitivity, specificity, and positive/negative predictive value.

Rationale: The paper does not include IC50 fold-change data.

Answer: No
"""

"""
Question: 6104 

Evidence: Population genotypic drug resistance testing of the pol region was performed … Diagnostic accuracy of LPV exposure testing … 

Rationale: No phenotypic susceptibility assay was used or described in the paper.

Answer: NA
"""

"""
Question: 6105 

Evidence: Population genotypic drug resistance testing of the pol region was performed … Assessment of different LPV detection thresholds … 

Rationale: Replication capacity was not measured or reported.

Answer: No
"""

"""
Question: 6106 

Evidence: Population genotypic drug resistance testing of the pol region was performed … Diagnostic accuracy of LPV exposure testing … 

Rationale: The study did not conduct phenotypic susceptibility testing for any drugs.

Answer: NA
"""

"""
Question: 7101 

Evidence: Population-based genotypic drug resistance testing was performed using previously described methods for plasma and for DBS. This is a retrospective analysis of adult (≥18 years) people living with HIV attending public healthcare facilities.

Rationale: The study analyzed clinical samples; there is no indication of constructing site-directed mutant isolates.

Answer: No
"""

"""
Question: 7102 

Evidence: This is a retrospective analysis of adult (≥18 years) people living with HIV attending public healthcare facilities. Population genotypic drug resistance testing of the pol region was performed on plasma and DBS using standard clinical protocols.

Rationale: No in vitro passage experiments are described; the data are from patient-derived samples.

Answer: No
"""